Bariki Mtafya

High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial

Martin J. Boeree, Norbert Heinrich, Rob E. Aarnoutse et al. · The Lancet Infectious Diseases · 2016 · 379 citations · Full text

Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial

Jonny Peter, Lynn S. Zijenah, Duncan Chanda et al. · The Lancet · 2016 · 262 citations

Pulmonary Tuberculosis, Treatment And Prevention, Medicine +12

Rapid and Accurate Detection of Mycobacterium tuberculosis in Sputum Samples by Cepheid Xpert MTB/RIF Assay—A Clinical Validation Study

Andrea Rachow, Alimuddin Zumla, Norbert Heinrich et al. · PLoS ONE · 2011 · 161 citations · Full text

Increased and Expedited Case Detection by Xpert MTB/RIF Assay in Childhood Tuberculosis: A Prospective Cohort Study

Andrea Rachow, Petra Clowes, Elmar Saathoff et al. · Clinical Infectious Diseases · 2012 · 142 citations · Full text

Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients

Norbert Heinrich, Rodney Dawson, Jeannine du Bois et al. · Journal of Antimicrobial Chemotherapy · 2015 · 91 citations · Full text